Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colon-targeted FMT plus PD-1 inhibitor for advanced refractory colorectal cancer
ChiCTR2300078672Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing University of Chinese Medicine
- Start
- Dec 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic fecal microbiota in colorectal cancer (CRC) (2 arms), sponsored by The Second Affiliated Hospital of Nanjing University of Chinese Medicine. Primary endpoint: Progression-free survival. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300078672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078672.